XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$27.64 USD
+1.24 (4.70%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $27.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
XOMA 27.64 +1.24(4.70%)
Will XOMA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XOMA
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
Other News for XOMA
XOMA Stock Dips Amidst Biotech Sector Decline
XOMA Stock Soars 5.17% Amid Positive Financial Performance and Analyst Ratings
XOMA Surges 5.46% on Positive Financial Metrics
Zevra?s MIPLYFFA? (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
XOMA Royalty Declares Quarterly Preferred Stock Dividends